Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

Prevalence of Systemic Inflammation in Patients With Atherosclerotic Cardiovascular Disease and Heart Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06122961

Acronym

POSEIDON

Enrollment

18198

Registered

2023-11-08

Start date

2023-11-23

Completion date

2025-04-30

Last updated

2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk, Chronic Kidney Disease, Heart Failure

Brief summary

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease). Participants will continue their normal care and will not get any treatment other than those the study doctor has prescribed.

Interventions

OTHERNo treatment given

No treatment given

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study. 2. Age 18 years or above at the time of signing the informed consent. 3. Presence of ASCVD (atherosclerotic cardiovascular disease) and/or HF (heart failure) 4. Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only).

Exclusion criteria

1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Current participation (i.e., signed informed consent) in any other interventional clinical study. 3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. Clinical evidence, or suspicion of, active infection within the last 60 days. 5. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation

Design outcomes

Primary

Measure	Time frame	Description
High sensitivity C-reactive protein (hsCRP) greater than or equal to 2 mg/L (yes/ no)	At visit (day 0)	Count of patient

Secondary

Measure	Time frame	Description
Interleukin 6 (IL-6)	At visit (day 0)	pg/ml
N-terminal prohormone of brain natriuretic peptide (NT-proBNP)	At visit (day 0)	pg/ml

Countries

Argentina, Australia, Brazil, Canada, China, Czechia, Denmark, France, Germany, India, Italy, Norway, Poland, South Korea, Sweden, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026